


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

**SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO
DISCLOSEABLE TRANSACTION
FULL ACQUISITION OF LANOVA MEDICINES**

Reference is made to the announcement (the “**Announcement**”) of Sino Biopharmaceutical Limited (the “**Company**”) dated July 15, 2025 in relation to the discloseable transaction relating to the full acquisition of LaNova Medicines. This supplemental announcement is made to (1) provide additional information on certain Vendors; and (2) update the financial information of LaNova Medicines. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

(1) Additional Information on Certain Vendors

The Company wishes to supplement additional information on the following Vendors.

QM162 is a company incorporated in Hong Kong and is owned by Qiming Venture Partners VII, L.P. (“**Qiming Partners VII**”) and Qiming VII Strategic Investors Fund, L.P. (“**Qiming VII Strategic**”). Qiming Partners VII and Qiming VII Strategic are exempted limited partnerships registered under the laws of the Cayman Islands. Qiming Partners VII has a wide investor base with 125 limited partners, each holds less than one-third of the partnership interests therein. Qiming VII Strategic has a wide investor base with 31 limited partners, each holds less than one-third of the partnership interests therein. Qiming GP VII, LLC is the general partner of both Qiming Partners VII and Qiming VII Strategic (collectively, the “**Qiming VII Funds**”). Qiming GP VII, LLC does not have ownership over Qiming VII Funds. However, as the general partner, investment and management’s decision-making power of Qiming VII Funds are wholly held and exercised by Qiming GP VII, LLC and all limited partners are passive investors of Qiming VII Funds. Qiming GP VII, LLC is controlled by Mr. Duane Ziping Kuang, Mr. Gary Rieschel, Ms. Suk Han Grace Lee and Mr. Ho Man Lam. Both Qiming Partners VII and Qiming VII Strategic are venture capital funds operated under Qiming Venture Partners focusing on investments in companies in the technology and consumer (T&C) and healthcare sectors across China.

Shanghai Jialang is a limited partnership established under the laws of the PRC. Shanghai Jialang is owned as to 3.2258% by its general partner, Hony Capital (Shanghai) Co., Ltd.* (弘毅投資(上海)有限公司) (“**Hony Shanghai**”) and 96.7742% by its limited partner, Hony (Tibet) Mezzanine Investment Management Centre (Limited Partnership)* (西藏弘毅夾層企業管理中心(有限合夥)) (“**Hony Tibet**”). Hony Shanghai is ultimately owned as 33.3% by Mr. Zhao Wen (趙文), 33.3% by Mr. Cao Yonggang (曹永剛) and 33.3% by Mr. Xu Minsheng (徐敏生). Hony Tibet is owned as to 10% by its general partner, Hongyi Enterprise Holdings (Shenzhen) Co., Ltd.* (弘毅企業控股(深圳)有限公司) (“**Hony Shenzhen**”) and 90% by its limited partner, Hony Capital Investment Management (Tianjin) L.P.* (弘毅私募基金管理(天津)合夥企業(有限合夥)). Hony Shenzhen was a wholly owned subsidiary of Hony Capital Limited(弘毅投資管理有限公司). Hony Capital Investment Management (Tianjin) L.P. is owned as to 0.6623% by its general partner, Hony Shenzhen and as to 99.3377% by its limited partner, Hongyi Holdings (Shenzhen) Enterprise (Limited Partnership)* (弘毅控股(深圳)企業(有限合夥)). Hongyi Holdings (Shenzhen) Enterprise (Limited Partnership) is owned as to 0.1996% by its general partner, Hony Shenzhen and as to 99.8004% by its limited partner, United Strength Silver Limited. United Strength Silver Limited is ultimately controlled by Mr. Cao Yonggang (曹永剛), Mr. Xu Minsheng (徐敏生), and Mr. Zhao John Huan (趙令歡).

Summer Starry is a company incorporated in the British Virgin Islands with limited liability and is owned as to 94.9% by Summer Healthcare Fund, L.P. (“**Summer Healthcare Fund**”). Summer Starry primarily engages in investment holding. Summer Healthcare Fund has a wide investor base with 27 limited partners, each holds less than one-third of the partnership interests therein. The general partner of Summer Healthcare Fund is Summer Capital GP Limited, which is ultimately controlled by Summer Capital Limited (“**Summer Capital**”). Summer Capital is a multi-strategy investment advisory company, focusing on advising investments in healthcare, blockchain, fintech and technology-drive consumption sectors. Summer Capital is ultimately controlled by Mr. Birong Zhang (張碧蓉).

(2) Updated Financial Information of LaNova Medicines

The Company has received updated financial information for LaNova Medicines Group from LaNova Medicines. According to LaNova Medicines, its unaudited consolidated financial information for the six months ended 30 June 2025 has recently been reviewed and approved by the board of directors of LaNova Medicines, with the details **in which the updated information is represented by fonts in bold and underlined** as set out below:

For the six months ended 30 June 2025, the unaudited consolidated revenue of LaNova Medicines Group amounted to RMB4,217,691,621, net profit before taxation amounted to RMB2,337,825,483, and net profit after taxation amounted to RMB1,685,236,190. As at 30 June 2025, the unaudited consolidated total assets of LaNova Medicines Group amounted to RMB2,094,479,675, **and net assets amounted to RMB1,932,906,786.**

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 22 July 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.

* *For identification purpose only*